Results 11 to 20 of about 12,682 (143)

Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components. [PDF]

Clin Pharmacol Drug Dev
Abstract Co‐administration of atorvastatin and fenofibrate has demonstrated clinical benefits in patients with dyslipidemia. To improve convenience and adherence, a fixed‐dose combination (FDC) of the two agents has gained interest. This study aimed to compare the pharmacokinetics (PKs) and safety of an FDC of atorvastatin/fenofibrate 20/145 mg with ...
Lee S, Khwarg J, Bae S, Park DM, Park H, Lee S, Yu KS.   +6 more
europepmc   +2 more sources

Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy. [PDF]

Pharmacotherapy
ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Clements JN, Mesawich J, Twisdale C.
europepmc   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization

Biology, 2021
Macular edema caused by retinal vascular leakage and ocular neovascularization are the leading causes of severe vision loss in diabetic retinopathy (DR) and age-related macular degeneration (AMD) patients.
Li Huang, Wentao Liang, Kelu Zhou, Ronald A. Wassel, Zachary D. Ridge, Jian-Xing Ma, Bing Wang   +6 more
doaj   +1 more source

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression

Journal of Lipid Research, 2007
In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester ...
Caroline C. van der Hoogt, Willeke de Haan, Marit Westerterp, Menno Hoekstra, Geesje M. Dallinga-Thie, Johannes A. Romijn, Hans M.G. Princen, J. Wouter Jukema, Louis M. Havekes, Patrick C.N. Rensen   +9 more
doaj   +1 more source

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

Frontiers in Pharmacology, 2022
Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown.
Dan Zhang, Shanzhuang Niu, Yicheng Ma, Hang Chen, Yu Wen, Mingke Li, Bo Zhou, Yi Deng, Chunjing Shi, Guangyu Pu, Meng Yang, Xianmei Wang, Chenggang Zou, Yuanli Chen, Lanqing Ma   +14 more
doaj   +1 more source

Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome

Journal of Lipid Research, 2012
We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS). We studied 11 MetS men in a randomized, double-blind, crossover trial.
Esther M.M. Ooi, Theodore W.K. Ng, Gerald F. Watts, Dick C. Chan, P. Hugh R. Barrett   +4 more
doaj   +1 more source

Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia

Biomedical and Biotechnology Research Journal, 2020
Background: Dyslipidemia (DL) is a blood lipid disorder characterized by high cholesterol, triglyceride and low density lipoprotein with reduction of high density lipoprotein.
Huda A Rasheed, Nawar R Hussien, Marwa S Al-Naimi, Hayder M Al-Kuraishy, Ali I Al-Gareeb   +4 more
doaj   +1 more source

Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia

Frontiers in Pharmacology, 2019
P-glycoprotein (P-gp) is a membrane-bound transporter encoded by Mdr1a/Abcb1a and Mdr1b/Abcb1b genes in rodents involved in the efflux of cytotoxic chemicals and metabolites from cells.
Martin Poruba, Zuzana Matuskova, Zuzana Matuskova, Martina Hüttl, Hana Malinska, Olena Oliyarnyk, Irena Markova, Sona Gurska, Ludmila Kazdova, Rostislav Vecera   +9 more
doaj   +1 more source

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate

Biology, 2014
Lipoprotein subclass concentrations are modifiable markers of cardiovascular disease risk. Fenofibrate is known to show beneficial effects on lipoprotein subclasses, but little is known about the role of genetics in mediating the responses of lipoprotein
Alexis C. Frazier-Wood, Mary K. Wojczynski, Ingrid B. Borecki, Paul N. Hopkins, Chao-Qiang Lai, Jose M. Ordovas, Robert J. Straka, Micheal Y. Tsai, Hemant K. Tiwari, Donna K. Arnett   +9 more
doaj   +1 more source